GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (NAS:GNVC) » Definitions » Intrinsic Value: Projected FCF

Genvec (Genvec) Intrinsic Value: Projected FCF : $0.00 (As of May. 06, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genvec Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-06), Genvec's Intrinsic Value: Projected FCF is $0.00. The stock price of Genvec is $7.193. Therefore, Genvec's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Genvec's Intrinsic Value: Projected FCF or its related term are showing as below:

GNVC's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.39
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Genvec Intrinsic Value: Projected FCF Historical Data

The historical data trend for Genvec's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Intrinsic Value: Projected FCF Chart

Genvec Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -98.25 -97.07 -50.65 -41.00 -28.71

Genvec Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.79 -32.28 -27.97 -28.71 -30.74

Competitive Comparison of Genvec's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Genvec's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genvec's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genvec's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Genvec's Price-to-Projected-FCF falls into.



Genvec Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Genvec's Free Cash Flow(6 year avg) = $-7.43.

Genvec's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar17)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-7.42608+0.583*0.8)/2.274
=-30.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genvec  (NAS:GNVC) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Genvec's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=7.193/-30.88500113446
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genvec Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Genvec's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Genvec (Genvec) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.
Executives
Wayne T Hockmeyer director ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Michael Richman director 2635 TECHNOLOGY FOREST BLVD., HOUSTON TX 77381
Marc R Schneebaum director GENVEC, INC., 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Douglas J Swirsky director, officer: President and CEO C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Willam N Kelley director MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ecor1 Capital Fund Qualified, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. other: See Explanation of Responses 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Zola P Horovitz director C/O GENAERA CORP, 5110 CAMPUS DDRIVE, PLYMOUTH MEETING PA 19462
Cynthia Collins director, officer: President & CEO 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Adel Mahmoud director
Joshua Ruch director 4 DUNE ROAD, EAST QUOGUE NY 11942

Genvec (Genvec) Headlines

From GuruFocus

GenVec Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-11-2011

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 05-08-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-07-2010

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-06-2009

GenVec Inc. Reports Operating Results (10-Q)

By gurufocus 08-07-2009